Drug intelligence / Profile preview

CE 008

Development stage: Preclinical
Lead developer: Cello Therapeutics
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Covalent Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

CE 008 is a cellular nanoparticle (CNP) chemotherapy drug under development by Cello Therapeutics. It is classified as an antineoplastic and drug conjugate, designed for the treatment of colorectal cancer and gastric cancer. The precise mechanism of action has not been defined or disclosed publicly. As a new molecular entity, it represents an innovative approach in oncology therapeutics utilizing membrane-encapsulated nanoparticles to potentially enhance delivery and efficacy of chemotherapeutic agents[2].

Beyond the preview

Go deeper on CE 008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE 008.

Explore the full profile